How has the COVID-19 pandemic impacted biomanufacturing operations?

SARS-CoV-2 and Biomanufacturing

Filling vaccine vials and syringes must be fast and GMP-compliant.

Need for Fill/Finish Inspection Speed

Facility, equipment design, and experience matter. 

Rapid Changeovers in Biologics Manufacturing

Topic

Articles

Wacker will support production of CureVac’s COVID-19 mRNA-based vaccine candidate at its biotech site in Amsterdam, with production scheduled to start in the first half of 2021.

CureVac and Wacker Sign Manufacturing Contract for COVID-19 Vaccine Candidate

The new super plant, being built in Incheon, South Korea, will have a total biopharmaceutical manufacturing capacity of 256,000 L.

Samsung Biologics Begins Construction on Fourth Biopharma Manufacturing Plant 

The companies have formed a long-term manufacturing agreement to accelerate the global supply for Lilly’s COVID-19 antibody therapeutics.

Samsung Biologics and Lilly Partner to Accelerate Delivery of COVID-19 Antibody Therapeutics

The agreement follows a recent announcement that Sartorius plans to invest $100 million in Songdo, South Korea’s bio cluster.

Samsung Biologics Signs MOU with Sartorius to Enhance Supply Chain for Biomedicines

The agreement will allow Roche to use CEVEC’s proprietary ELEVECTA technology, which is designed to enable fully scalable, high-performance AAV vector production in suspension bioprocesses.

Roche in Agreement to Use CEVEC’s ELEVECTA Technology for AAV Manufacture

Apiject was approved for a $590-million loan from the US to build in-country capacity for COVID-19 vaccines and therapeutics. 

ApiJect to Build US Facilities for Needle Hubs and Prefilled Syringes

CordenPharma has announced the expansion of its non-GMP SPPS manufacturing capacity at its Centre of Excellence for Peptide Process Development and non-GMP manufacturing in Frankfurt, Germany.

CordenPharma Expands Non-GMP Solid-Phase Peptide Synthesis Manufacturing Capacity

A second global Phase III clinical trial investigating the safety and efficacy of a two-dose regimen of JNJ-78436735 has been initiated by Johnson & Johnson.

Johnson & Johnson Starts Second Global Phase III Clinical Trial of Janssen COVID-19 Vaccine

Bone Therapeutics has reported the completion of Catalent’s acquisition of Skeletal Cell Therapy Support SA (SCTS)—Bone Therapeutics’ cell therapy manufacturing subsidiary.

Catalent Completes Acquisition of Bone Therapeutics’ Cell Therapy Manufacturing Subsidiary

Interim results of AZD1222 trial have demonstrated lower reactogenicity in older adults, and strong immune responses across all adult age groups.

Interim Results Show Strong Immune Responses and Better Tolerability in Older Adults for AZD1222

Cleanroom Equipment and Supplies

Clinical Trial Materials